Vor Biopharma Inc (VOR) - Total Assets
Based on the latest financial reports, Vor Biopharma Inc (VOR) holds total assets worth $481.05 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Vor Biopharma Inc - Total Assets Trend (2018–2025)
This chart illustrates how Vor Biopharma Inc's total assets have evolved over time, based on quarterly financial data. Also see VOR stock market capitalisation for the company's overall valuation and market capitalisation.
Vor Biopharma Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Vor Biopharma Inc's total assets of $481.05 Million consist of 98.7% current assets and 1.3% non-current assets. Review Vor Biopharma Inc debt and liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 85.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Vor Biopharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Vor Biopharma Inc stock quote for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Vor Biopharma Inc's current assets represent 98.7% of total assets in 2025, an increase from 93.0% in 2018.
- Cash Position: Cash and equivalents constituted 85.4% of total assets in 2025, down from 92.3% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Vor Biopharma Inc Competitors by Total Assets
Key competitors of Vor Biopharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Vor Biopharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 19.15 | 3.49 | 25.20 |
| Quick Ratio | 19.15 | 3.49 | 25.20 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $450.29 Million | $146.15 Million | $222.86 Million |
Vor Biopharma Inc - Advanced Valuation Insights
This section examines the relationship between Vor Biopharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.66 |
| Latest Market Cap to Assets Ratio | 2.79 |
| Asset Growth Rate (YoY) | 224.8% |
| Total Assets | $464.13 Million |
| Market Capitalization | $1.30 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Vor Biopharma Inc's assets at a significant premium (2.79x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Vor Biopharma Inc's assets grew by 224.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Vor Biopharma Inc (2018–2025)
The table below shows the annual total assets of Vor Biopharma Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $464.13 Million | +224.81% |
| 2024-12-31 | $142.89 Million | -31.90% |
| 2023-12-31 | $209.83 Million | -29.91% |
| 2022-12-31 | $299.37 Million | +23.40% |
| 2021-12-31 | $242.59 Million | +219.58% |
| 2020-12-31 | $75.91 Million | +672.52% |
| 2019-12-31 | $9.83 Million | +875.77% |
| 2018-12-31 | $1.01 Million | -- |
About Vor Biopharma Inc
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with Re… Read more